ObjectiveCheckpoint inhibitor pneumonitis (CIP) is a potentially life-threatening immune-related adverse event. Efficient strategies to select patients at risk are still required. The aim of our study was to assess the utility of a machine learning model, integrating pre-treatment CT lung radiomics features with clinical data, to predict patients at risk of developing CIP.MethodsIn this retrospective study, 116 patients with varied malignancies treated with immune checkpoint inhibitors (ICIs) were included. In this cohort, 35 patients presented with CIP and 81 patients did not. Each lung and its lobes were segmented on pre-treatment CT scans to perform a handcrafted radiomic analysis. Radiomic features were associated with clinical parameters to build generalized linear (GLM) and random forest (RF) models, to predict occurrence of CIP. The models were fine-tuned, validated and tested using a nested 5-fold cross-validation method.ResultsThe RF models combining radiomic and clinical features showed the best performances with an area under the ROC curve (AUC) of 0.75 (95%CI:0.62-0.88) on the test set. The most accurate clinical model was a RF model and achieved an AUC of 0.72 (95%CI:0.51-0.92). The best radiomic model was a GLM model and achieved an AUC of 0.71 (95%CI:0.58-0.84).ConclusionsOur CT-based lung radiomic models showed moderate to good performance at predicting CIP. We demonstrated the potential role of machine learning models associating clinical parameters and lung CT radiomic features to better identify patients treated with ICIs at risk of developing CIP.Advances in knowledge: Radiomics analysis of the lung parenchyma could be used as a non-invasive tool to select patients at risk of developing immune-checkpoint pneumonitis.
Keywords: immune checkpoint inhibitors; immune checkpoint pneumonitis; immune-related adverse events; machine learning; radiomics.